Bleeding-Linked Hospitalization Up With Amiodarone in A-Fib
TUESDAY, May 23, 2023 (HealthDay News) — For patients with atrial fibrillation receiving apixaban or rivaroxaban, the risk of bleeding-related hospitalizations is greater during amiodarone treatment than flecainide or sotalol, according to a study pu…
Learn MoreRisk for GI Bleed Increased With Hemodialysis Versus Peritoneal Dialysis
THURSDAY, Jan. 19, 2023 (HealthDay News) — The risk for newly diagnosed gastrointestinal (GI) bleeding is increased for patients undergoing hemodialysis (HD) versus peritoneal dialysis (PD), according to a study published online Jan. 2 in Scientific …
Learn MoreNetwork Meta-Analysis Compares DOACs to LMWH for Cancer-Linked Thrombosis
TUESDAY, Dec. 27, 2022 (HealthDay News) — Direct oral anticoagulants (DOACs) are more effective and cost-effective than low-molecular-weight heparin for cancer-associated thrombosis (CAT), with the results sensitive to monthly drug costs, according t…
Learn MoreUna segunda muerte en un ensayo sobre un medicamento experimental para el Alzheimer es preocupante
MARTES, 29 de noviembre de 2022 (HealthDay News) — Ya han muerto dos personas por hemorragias en el cerebro que podrían estar vinculadas con un medicamento experimental para el Alzheimer, lo que pone en duda la seguridad del fármaco.Una mujer de 65 a…
Learn MoreSecond Death in Trial of Experimental Alzheimer’s Drug Is Raising Concerns
TUESDAY, Nov. 29, 2022 (HealthDay News) — Two people have now died from brain hemorrhages that may be linked to an experimental Alzheimer’s drug, calling into question the medication’s safety.A 65-year-old woman with early-stage Alzheimer’s recently …
Learn MoreAHA: Once-Daily Edoxaban Seems Safe for Pediatric Cardiac Patients
FRIDAY, Nov. 4, 2022 (HealthDay News) — Once-daily edoxaban seems safe and effective for pediatric patients with cardiac disease, according to a study presented at the American Heart Association Scientific Sessions 2022, held from Nov. 5 to 7 in Chic…
Learn MoreGI Bleeding Lower With Apixaban Versus Other DOACs in A-Fib
TUESDAY, Nov. 1, 2022 (HealthDay News) — For patients with atrial fibrillation (AF), apixaban use is associated with a lower risk for gastrointestinal bleeding (GIB) compared with other direct oral anticoagulants (DOACs), according to a study publish…
Learn MoreBenefit of Ticagrelor-Aspirin in Stroke Patients Tied to Renal Function
TUESDAY, Nov. 1, 2022 (HealthDay News) — Among CYP2C19 loss-of-function allele carriers with minor stroke or transient ischemic attack, those with normal renal function rather than impaired renal function derive greater benefit from ticagrelor-aspiri…
Learn MoreApixaban Compared to Rivaroxaban for A-Fib and Valvular Heart Disease
WEDNESDAY, Oct. 19, 2022 (HealthDay News) — For patients with atrial fibrillation (AF) and valvular heart disease (VHD), apixaban is associated with a reduced risk for ischemic stroke or systemic embolism and a reduced risk for bleeding compared with…
Learn MoreApixaban Noninferior to Enoxaparin for Postoperative VTE Prophylaxis
TUESDAY, Sept. 27, 2022 (HealthDay News) — Apixaban is noninferior to enoxaparin for extended-duration venous thromboembolic event prophylaxis (EP) after abdominopelvic oncologic surgery, according to a study published in the October issue of The Jou…
Learn More